Literature DB >> 17430107

Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide.

Ernst R Werner1, G Werner-Felmayer.   

Abstract

Much attention has been paid in initial biochemical studies on the ability of indoleamine 2,3-dioxygenase to use superoxide as substrate to cleave tryptophan to N-formyl kynurenine. This ability, however, is limited to the ferric form of the enzyme only, whereas the ferrous form requires oxygen rather than superoxide as substrate. As long as the enzyme is held in the ferrous form, high yield formation of product proceeds from the ferrous oxygen tryptophan ternary complex without the participation of superoxide. Enzyme assays in homogenates are carried out in presence of Methylene Blue, ascorbate and catalase. Ascorbate can be replaced by other reductants like e.g. tetrahydrobiopterin. Experiments with alteration of intracellular tetrahydrobiopterin concentrations in intact interferon-gamma treated cells clearly showed that tetrahydrobiopterin is not required for the indoleamine 2,3-dioxygenase reaction. In homogenates of interferon-gamma treated T-24 cells, substrates of xanthine oxidase did not stimulate the indoleamine 2,3-dioxygenase reaction, nor did allopurinol inhibit the reaction, nor did superoxide dismutase alter indoleamine 2,3-dioxygenase activity irrespective of the reductant used. From these experiments we concluded that molecular oxygen rather than superoxide is used in cell homogenates by indoleamine 2,3-dioxygenase to cleave L-tryptophan. A detailed analysis of available reports on oxygen and superoxide utilization by indoleamine 2,3-dioxygenase gives a comprehensive picture that the enzyme uses oxygen bound to the ferrous enzyme for cleavage of tryptophan, that the enzyme needs to be held by reductants in the ferrous state in enzyme incubations, and that superoxide is one of the reductants capable performing this reduction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430107      PMCID: PMC2851152          DOI: 10.2174/138920007780362482

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  34 in total

Review 1.  Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism.

Authors:  Osamu Takikawa
Journal:  Biochem Biophys Res Commun       Date:  2005-09-15       Impact factor: 3.575

2.  Inhibition of indoleamine 2,3 dioxygenase activity by H2O2.

Authors:  Anne Poljak; Ross Grant; Chris J D Austin; Joanne F Jamie; Robert D Willows; Osamu Takikawa; Tamantha K Littlejohn; Roger J W Truscott; Mark J Walker; Perminder Sachdev; George A Smythe
Journal:  Arch Biochem Biophys       Date:  2006-03-20       Impact factor: 4.013

3.  Possible participation of superoxide anion in the intestinal tryptophan 2,3-dioxygenase reaction.

Authors:  F Hirata; O Hayaishi
Journal:  J Biol Chem       Date:  1971-12-25       Impact factor: 5.157

Review 4.  Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy.

Authors:  Andrew L Mellor; Phillip Chandler; Geon Kook Lee; Theodore Johnson; Derin B Keskin; Jeffrey Lee; David H Munn
Journal:  J Reprod Immunol       Date:  2002 Oct-Nov       Impact factor: 4.054

5.  Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes.

Authors:  S Yamamoto; O Hayaishi
Journal:  J Biol Chem       Date:  1967-11-25       Impact factor: 5.157

6.  The heme environment of recombinant human indoleamine 2,3-dioxygenase. Structural properties and substrate-ligand interactions.

Authors:  Andrew C Terentis; Shane R Thomas; Osamu Takikawa; Tamantha K Littlejohn; Roger J W Truscott; Robert S Armstrong; Syun-Ru Yeh; Roland Stocker
Journal:  J Biol Chem       Date:  2002-02-26       Impact factor: 5.157

7.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Authors:  Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

Review 8.  Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.

Authors:  David H Munn
Journal:  Curr Opin Immunol       Date:  2006-02-07       Impact factor: 7.486

9.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase.

Authors:  Hiroshi Sugimoto; Shun-ichiro Oda; Takashi Otsuki; Tomoya Hino; Tadashi Yoshida; Yoshitsugu Shiro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 10.  Indoleamine-2,3-dioxygenase modulation of allergic immune responses.

Authors:  Annie V Le; David H Broide
Journal:  Curr Allergy Asthma Rep       Date:  2006-02       Impact factor: 4.919

View more
  5 in total

Review 1.  Why are epididymal tumours so rare?

Authors:  Ching-Hei Yeung; Kai Wang; Trevor G Cooper
Journal:  Asian J Androl       Date:  2012-04-23       Impact factor: 3.285

Review 2.  Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.

Authors:  Abdulla A-B Badawy
Journal:  Int J Tryptophan Res       Date:  2017-03-15

Review 3.  Mechanisms of Fish Macrophage Antimicrobial Immunity.

Authors:  Leon Grayfer; Baris Kerimoglu; Amulya Yaparla; Jordan W Hodgkinson; Jiasong Xie; Miodrag Belosevic
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

Review 4.  The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases.

Authors:  Knut Hestad; Jan Alexander; Helge Rootwelt; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-07-18

5.  Cytotoxicity of ferulic Acid on T24 cell line differentiated by different microenvironments.

Authors:  Chiung-Chi Peng; Charng-Cherng Chyau; Hui-Er Wang; Chi-Huang Chang; Kuan-Chou Chen; Kuang-Yu Chou; Robert Y Peng
Journal:  Biomed Res Int       Date:  2013-05-08       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.